Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
| Revenue (TTM) | $1.92B |
| Gross Profit (TTM) | $1.02B |
| EBITDA | $563.91M |
| Operating Margin | 23.70% |
| Return on Equity | 1.51% |
| Return on Assets | 2.89% |
| Revenue/Share (TTM) | $4.46 |
| Book Value | $12.42 |
| Price-to-Book | 3.91 |
| Price-to-Sales (TTM) | 11.20 |
| EV/Revenue | 11.51 |
| EV/EBITDA | 59.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.00% |
| Shares Outstanding | $90.05M |
| Float | $79.98M |
| % Insiders | 13.61% |
| % Institutions | 67.66% |
Volatility is currently expanding
The mean of analysts' price targets for Arxis (ARXS) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arxis, Inc. ( ARXS ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Bryan Wendlandt - Head of FP&A and Investor Relations Kevin Perhamus - President, CEO & Director Azad Badakhsh - CFO & Treasurer Conference Call Participants Sheila Kahyaoglu - Jefferies LLC, Research Division Kristine Liwag - Morgan Stanley, Research Division Peter Arment - Robert W. Baird & Co. Incorporated, Research Division John Godyn - Citigroup Inc. Exchange Research Scott Mikus - Melius Research LLC Gregory Dahlberg - Wolfe Research, LLC Connor Dessert - Goldman Sachs Group, Inc., Research Division Kenneth Herbert - RBC Capital Markets, Research Division Noah Levitz - William Blair & Company L.L.C.
Arxis NASDAQ: ARXS reported third-quarter 2026 revenue of $564 million, up 36% from a year earlier, as organic growth, pricing and production increases on existing programs lifted results. Adjusted EBITDA rose 67% to $256 million, while adjusted EBITDA margin expanded 840 basis points to 45.4%.
BLOOMFIELD, Conn., Oct. 28, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, today reported financial results for the third quarter ended September 30, 2026.
BLOOMFIELD, Conn., Oct. 15, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) today announced that it will release its financial results for the third quarter of 2026 after the market closes on Wednesday, October 28, 2026.
BLOOMFIELD, Conn., Sept. 3, 2026 /PRNewswire/ -- Arxis, Inc. (Nasdaq: ARXS) (the "Company" or "Arxis"), a publicly traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced that it completed the acquisitions of Schatz Bearing Corporation ("Schatz") on September 2, 2026, and StratEdge Corporation ("StratEdge") on September 1, 2026.
BLOOMFIELD, Conn., Aug. 18, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced that it has completed its previously announced acquisition of Omnetics Connector Corporation ("Omnetics").
Arxis, Inc. (ARXS) Q2 2026 Earnings Call Transcript
Arxis NASDAQ: ARXS reported second-quarter sales of $501 million, up 25% from a year earlier, as organic growth, pricing and acquisitions contributed to broad-based gains across its businesses and end markets.
BLOOMFIELD, Conn., July 29, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS)(the "Company" or "Arxis"), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, today reported financial results for the second quarter ended June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARXS and any ticker you trade — then tracks every position and per-strategy win rate.
